Skip to content

Docteur Calomne

Active Private limited companyfounded 2009active for 17 yearsRue de Royenne 31, 1390 Grez-DoiceauKBO/BCE: BE 0810.058.480

Lifetime

17 annual accounts with figures on one time axis
Gross marginpeak €130,373 (2025)
€130,373▲ 25.8%
Resultpeak €82,526 (2014)
€46,935▲ 74.7%
Equitypeak €270,519 (2025)
€270,519▲ 21.0%
Debts
€39,566▼ 58.0%
Board1 name since 2009
1 directorValérie Calomne
Documentsfilings and deeds
31-08-202631 days late
2025micro format
Gross margin from €103,672 to €130,373Result from €26,867 to €46,935Equity from €223,584 to €270,519Debts from €94,254 to €39,566

Key points

from the 2025 annual accounts

Equity

€270,519 ▲ 21.0%

Docteur Calomne has made a profit in every financial year since 2009.

Liquidity

10.36 was 3.83 in 2024

Short-term debts fell from €74,519 to €27,570.

Filings

17 annual accounts since 2009
AprilJune31 JulyOctober2010201520202025

Ten of the last ten came late. The 2019 accounts came latest: 152 days after the end of the period.

Checked score

95
Excellent
Financially stronger than 63% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

The dashed line is the sector median: < 0.1% across 24,179 companies (NACE 86, micro).

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Last 24 months 12-2024: < 0.1% 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: < 0.1%● unchanged vs 07-2025 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: < 0.1%● unchanged vs 07-2026highest value 09-2026: < 0.1%● unchanged vs 08-2026lowest value 10-2026: < 0.1%● unchanged vs 09-2026lowest value 11-2026: < 0.1%● unchanged vs 10-2026lowest value

Financial strength
Strong

Solvency
100+5equity 87.2% of total assets
Liquidity
100+8short-term debt 8.9% · cash 65.6%
Profitability
57+12return on assets 15.1%

Score breakdown

raises risk
Last filed accounts filed 31 days late; 2 of the last 3 accounts late
lowers risk
Sector: Human health activities (NACE 86)
Liquidity: current ratio 10.36, cash €203,431
Equity €270,519 (87.2% of total assets)
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 95% on liquidity, 9% on profitability and 65% on growth.

The bankruptcy probability was computed on 05-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

The probability rests on the annual accounts with balance sheet date 31-12-2025.

Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Comparable companies, two years later

In July 2024, 34,693 companies had the same profile as Docteur Calomne has now. Each dot stands for 87 companies, two years later.

95.3%
were still trading
3.9%
stopped another way
0.7%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

That fits the bankruptcy probability of Docteur Calomne itself: < 0.1% within 12 months.

Test of the method

The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 34,693 companies, not a prediction for Docteur Calomne. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit of up to €25,000 on 30-day terms is acceptable

Liquidity is ample, with a current ratio of 10.36 (3.83 in 2024), above the usual 1.5. Short-term debt is 8.9% and cash 65.6% of total assets. 12.8% of the assets are financed with debt and provisions.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Five signals.
lowers riskraises risk
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Liquidity: current ratio 10.36, cash €203,431
NBB · annual accounts
raises risk · Last filed accounts filed 31 days late; 2 of the last 3 accounts late
NBB · filings
lowers risk · Equity €270,519 (87.2% of total assets)
NBB · annual accounts
raises risk · 2025 accounts filed 31 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filings
Deviation from the deadline
2025
31 days late
2024
25 days late
2023
31 days late
2022
106 days late
2021
31 days late
2020
31 days late
2019
152 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 58 days after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 31 August (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
06-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Board and ownership

VC
Valérie Calomne
Director, since 23-02-2009
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0810058480
Legal-form change · Resignations & appointments “La société a pour objet l’exercice en son nom et pour son compte de la médecine, et ce par l’intermédiaire de…” (deed in French) · General meeting of 26-04-2023 · Gazette deed
First establishment Rue de Royenne 31, Grez-Doiceau
Incorporation published on 06-03-2009 · Gazette deed
All 30 events

Comparable companies

same main activity, similar in size and age
Company Total assets Gross margin Solvency Staff
Docteur Calomne Grez-Doiceau €310,085 €130,373 87.2% -
WALON Waterloo €312,986 €125,396 67.8% -
DOPAMINE Braine-le-Château €297,324 €134,363 95.0% -
DR ANDRIANTAFIKA MAMISOA Ittre €342,532 €126,945 90.8% -
NKN ANESTHESIA Waterloo €309,994 €122,041 79.7% -
Cabinet Médical Docteur Kaluanga Bwanga Liège €300,204 €127,712 84.6% -
DR. MC. DE JAEGER Wingene €330,845 €125,602 91.8% -

These companies have the same main activity as Docteur Calomne: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €297,000 and €343,000, founded between 2007 and 2011.

Official details

Source: KBO
Status
Active since 23-02-2009Normal situation
Activity
Specialist medical practiceNACE 86220
Establishment unit
2.360.171.5341390 Grez-Doiceau, since 26-04-2023
Financial year end
31 December
Peppol
Reachable since 24-11-2023
Company details

Annual accounts 2025

Turnover
≈ €240,000estimated
Total assets
€310,085▼ 2.4%
Filing
Filed on 31-08-2026
Financials

Insights on Docteur Calomne

Docteur Calomne files the micro format. That format states no turnover. The gross margin rose from €52,914 in 2009 to €130,373 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Docteur Calomne

What is the company number of Docteur Calomne?
The company number of Docteur Calomne is 0810.058.480. The VAT number is the same number with BE in front: BE 0810.058.480.
Where is Docteur Calomne based?
The registered office is at Rue de Royenne 31, 1390 Grez-Doiceau.Company details
What does Docteur Calomne do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of Docteur Calomne?
Docteur Calomne is a private limited company (BV).
When was Docteur Calomne founded?
Docteur Calomne was founded on 23-02-2009.
Is Docteur Calomne still active?
Yes, Docteur Calomne is an active enterprise in the KBO register.
What is the turnover of Docteur Calomne?
The turnover in financial year 2025 is ≈ €240,000. This figure is estimated from the gross margin of €130,373 and 42 comparable companies (NACE 86220). It probably lies between €210,000 and €320,000.Financials
Is Docteur Calomne profitable?
In financial year 2025, Docteur Calomne made a profit of €46,935.
Where can I find the annual accounts of Docteur Calomne?
Docteur Calomne filed 17 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Docteur Calomne due?
Docteur Calomne must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.